SCPH - scPharmaceuticals Inc.
IEX Last Trade
3.39
-0.005 -0.147%
Share volume: 7,710
Last Updated: Thu 26 Dec 2024 08:30:14 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$3.40
0.00
-0.15%
Fundamental analysis
24%
Profitability
25%
Dept financing
8%
Liquidity
50%
Performance
21%
Performance
5 Days
-1.17%
1 Month
-6.11%
3 Months
-23.53%
6 Months
-23.87%
1 Year
-47.10%
2 Year
-46.35%
Key data
Stock price
$3.39
DAY RANGE
$3.32 - $3.44
52 WEEK RANGE
$3.35 - $6.60
52 WEEK CHANGE
-$47.15
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: John H. Tucker
Region: US
Website: scpharmaceuticals.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: scpharmaceuticals.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
scPharmaceuticals Inc. engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is. delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms.
Recent news